Rhythm Pharmaceuticals, Inc. (RYTM)
RYTMNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$114.96
+3.70 (+3.33%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $7.90bn
- P/E
- –
- EPS, last 4 quarters
- $-2.90
- Dividend yield
- –
- Day range
- –
- 52-week range
- $74.50 to $122.20
- Average volume
- 1.08m
- Previous close
- $111.26
Analysts
15 coveringBuy14 buy, 1 hold, 0 sell
Targets a year out average $149.64, +30.2% from here
Earnings
next estimate $-2.55Next report
Dec 2025
+7.6%
Mar 2026
+3.5%
Jun 2026
+9.9%
Sep 2026
+10.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $57.25m | $60.11m | $71.25m | $92.13m |
| Gross profit | $52.45m | $52.95m | $62.32m | $79.96m |
| Operating income | -$47.06m | -$52.36m | -$48.55m | -$39.27m |
| Net income | -$47.51m | -$55.64m | -$49.30m | -$41.37m |
Last four quarters: revenue $280.75m, margin -69.0%, free cash flow –
News
8 latest- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split RTTNews · 3 days ago
- Rhythm Pharma (RYTM) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Rhythm Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Rhythm Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Product Revenue of $92.1 millionFintel · 6 days ago
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesZacks · 7 days ago
- Rhythm Amends LG Chem Deal, Secures Up To $750 Million Financing For Obesity Pipeline RTTNews · 7 days ago
- CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks · Oct 29, 2026
- Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 27, 2026
The company
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm's lead asset, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- rhythmtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.